Literature DB >> 17982479

Internalization: what does it tell us about pharmacokinetic and pharmacodynamic properties of an antagonist?

A Mueller1.   

Abstract

Chemokine receptors play an important role in trafficking leukocytes within the body, a process that depends on expression of the receptors on the cell surface. Expression levels are regulated by the rate of internalizing receptor compared to the rate of recycling/recovering receptor. Internalization is commonly induced by binding of agonists to their receptors that in turn use clathrin-coated pits or caveolae to internalize. Joplin and colleagues describe a novel usage of internalization assays to determine pharmacokinetic/pharmacodynamic relationships of an antagonist on CXCR3 in a murine system. Intriguingly their results show that internalization assays give robust data about the pharmacokinetics/pharmacodynamics of different agonists and antagonists in an in vivo model. This kind of assay will allow investigations of the pharmacological properties of agonists and antagonists in a completely different setting and also give new insight into the regulation of cell surface expression of chemokine receptors and other G protein-coupled receptors, which can lead to potential novel therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17982479      PMCID: PMC2189999          DOI: 10.1038/sj.bjp.0707521

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  7 in total

Review 1.  Dancing to the tune of chemokines.

Authors:  M Thelen
Journal:  Nat Immunol       Date:  2001-02       Impact factor: 25.606

2.  Pathways for internalization and recycling of the chemokine receptor CCR5.

Authors:  Anja Mueller; Eamonn Kelly; Philip G Strange
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

3.  Dominance of CCL22 over CCL17 in induction of chemokine receptor CCR4 desensitization and internalization on human Th2 cells.

Authors:  Margherita Mariani; Rosmarie Lang; Elisa Binda; Paola Panina-Bordignon; Daniele D'Ambrosio
Journal:  Eur J Immunol       Date:  2004-01       Impact factor: 5.532

4.  Cutting edge: human beta defensin 3--a novel antagonist of the HIV-1 coreceptor CXCR4.

Authors:  Zhimin Feng; George R Dubyak; Michael M Lederman; Aaron Weinberg
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

5.  Structure/function relationships of CCR8 agonists and antagonists. Amino-terminal extension of CCL1 by a single amino acid generates a partial agonist.

Authors:  James M Fox; Pilar Najarro; Geoffrey L Smith; Sofie Struyf; Paul Proost; James E Pease
Journal:  J Biol Chem       Date:  2006-10-05       Impact factor: 5.157

6.  CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11).

Authors:  A Sauty; R A Colvin; L Wagner; S Rochat; F Spertini; A D Luster
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

7.  Analysis of the pharmacokinetic/pharmacodynamic relationship of a small molecule CXCR3 antagonist, NBI-74330, using a murine CXCR3 internalization assay.

Authors:  L A Jopling; G F Watt; S Fisher; H Birch; S Coggon; M I Christie
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

  7 in total
  3 in total

1.  GPCR theme editorial.

Authors:  G Milligan; J C McGrath
Journal:  Br J Pharmacol       Date:  2009-09       Impact factor: 8.739

2.  Intracellular expression of purinoceptors.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2015-05-26       Impact factor: 3.765

3.  Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs.

Authors:  Emmanuelle Pradelli; Babou Karimdjee-Soilihi; Jean-François Michiels; Jean-Ehrland Ricci; Marie-Ange Millet; Fanny Vandenbos; Timothy J Sullivan; Tassie L Collins; Michael G Johnson; Julio C Medina; Eugenie S Kleinerman; Annie Schmid-Alliana; Heidy Schmid-Antomarchi
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.